Lunsumio

Active Ingredient(s): Mosunetuzumab-axgb
FDA Approved: * December 22, 2022
Pharm Company: * GENENTECH INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lunsumio 30 mg/30ml Intravenous Concentrate
NDC: 50242-142
Labeler:
Genentech, Inc.
Lunsumio 1 mg/ml Intravenous Concentrate
NDC: 50242-159
Labeler:
Genentech, Inc.